A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
Authors
Keywords
-
Journal
NATURE BIOTECHNOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-11-01
DOI
10.1038/s41587-022-01510-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Engineering interferons and interleukins for cancer immunotherapy
- (2022) Patrick G. Holder et al. ADVANCED DRUG DELIVERY REVIEWS
- PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells
- (2022) Laura Codarri Deak et al. NATURE
- Restoring IL-2 to its cancer immunotherapy glory
- (2021) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- 509 A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer
- (2021) Aung Naing et al. Journal for ImmunoTherapy of Cancer
- 717 Selective activation of CD8+ T cells by a CD8-targeted IL-2 results in enhanced anti-tumor efficacy and safety
- (2021) Kelly Moynihan et al. Journal for ImmunoTherapy of Cancer
- The advent of de novo proteins for cancer immunotherapy
- (2020) Alfredo Quijano-Rubio et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity
- (2020) Shanling Shen et al. Frontiers in Immunology
- ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
- (2020) Jared E Lopes et al. Journal for ImmunoTherapy of Cancer
- Designed protein logic to target cells with precise combinations of surface antigens
- (2020) Marc J. Lajoie et al. SCIENCE
- An engineered 4-1BBL fusion protein with “activity on demand”
- (2020) Jacqueline Mock et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Precise T cell recognition programs designed by transcriptionally linking multiple receptors
- (2020) Jasper Z. Williams et al. SCIENCE
- De novo design of potent and selective mimics of IL-2 and IL-15
- (2019) Daniel-Adriano Silva et al. NATURE
- What has de novo protein design taught us about protein folding and biophysics?
- (2019) David Baker PROTEIN SCIENCE
- Development of an Interleukin-12 Fusion Protein That Is Activated by Cleavage with Matrix Metalloproteinase 9
- (2019) Denise Skrombolas et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice
- (2019) Yushu Joy Xie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control
- (2019) Zhichen Sun et al. Nature Communications
- Chimeric antigen receptor–modified T cells: CD19 and the road beyond
- (2018) Alexander I. Salter et al. BLOOD
- Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
- (2018) Jonathan T. Sockolosky et al. SCIENCE
- Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
- (2018) Michael Dougan et al. Cancer Immunology Research
- Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy
- (2018) Cornelia Hutmacher et al. ADVANCED DRUG DELIVERY REVIEWS
- Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy
- (2018) Jamie B. Spangler et al. JOURNAL OF IMMUNOLOGY
- Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells
- (2017) Mohammad Rashidian et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cytokines in Cancer Immunotherapy
- (2017) Thomas A. Waldmann Cold Spring Harbor Perspectives in Biology
- PD-L1 is an activation-independent marker of brown adipocytes
- (2017) Jessica R. Ingram et al. Nature Communications
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- Targeted Reconstitution of Cytokine Activity upon Antigen Binding using Split Cytokine Antibody Fusion Proteins
- (2016) Dario Venetz et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The coming of age of de novo protein design
- (2016) Po-Ssu Huang et al. NATURE
- Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
- (2015) Eric F. Zhu et al. CANCER CELL
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
- (2015) Nabil Ahmed et al. JOURNAL OF CLINICAL ONCOLOGY
- Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution
- (2015) Alice Tzeng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease
- (2014) Mark D. Turner et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- High efficiency cell-specific targeting of cytokine activity
- (2014) Geneviève Garcin et al. Nature Communications
- Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
- (2013) M. Hudecek et al. CLINICAL CANCER RESEARCH
- Transnuclear TRP1-Specific CD8 T Cells with High or Low Affinity TCRs Show Equivalent Antitumor Activity
- (2013) S. K. Dougan et al. Cancer Immunology Research
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells
- (2011) S. Terakura et al. BLOOD
- A Low-Toxicity IL-2-Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
- (2011) S. D. Gillies et al. CLINICAL CANCER RESEARCH
- Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases
- (2011) John Puskas et al. IMMUNOLOGY
- Bispecific Designed Ankyrin Repeat Proteins (DARPins) Targeting Epidermal Growth Factor Receptor Inhibit A431 Cell Proliferation and Receptor Recycling
- (2011) Ykelien L. Boersma et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- DARPins Recognizing the Tumor-Associated Antigen EpCAM Selected by Phage and Ribosome Display and Engineered for Multivalency
- (2011) Nikolas Stefan et al. JOURNAL OF MOLECULAR BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now